1 – 18 of 18
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
- 2016
-
Mark
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
(
- Contribution to journal › Article
-
Mark
STAT5 induces miR-21 expression in cutaneous T cell lymphoma
(
- Contribution to journal › Article
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
(
- Contribution to journal › Article
- 2014
-
Mark
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
-
Mark
Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
(
- Contribution to journal › Article
- 2013
-
Mark
World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience
(
- Contribution to journal › Article
- 2012
-
Mark
A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis.
(
- Contribution to journal › Article
-
Mark
Upfront Autologuos Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01.
(
- Contribution to journal › Article
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
(
- Contribution to journal › Article
- 2011
-
Mark
Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)
(
- Contribution to journal › Article
- 2010
-
Mark
A Novel Immunohistochemical Sequential Multi Labelling and Erasing Technique Enables Epitope Characterization of Bone Marrow Pericytes In Primary Myelofibrosis
(
- Contribution to journal › Published meeting abstract
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(
- Contribution to journal › Article
-
Mark
Favorable Outcome In ALK Negative Anaplastic Large Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT) a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
-
Mark
Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy Associated T Cell Lymphoma a Prospective Study by the Nordic Lymphoma Group (NLG T 01)
(
- Contribution to journal › Published meeting abstract
- 2009
-
Mark
(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)
(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
(
- Contribution to journal › Article
- 2007
-
Mark
Role of Helicobacter pylori in conjunctival mucosa-associated lymphoid tissue lymphoma
(
- Contribution to journal › Article